IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

Stock Information for IGC Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About IGC Pharma Inc.

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
IGC Pharma Announces Equity Research Update by Alliance Global Partners
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.